Feedback

Obesity Snapshot (EN): The Evidence Evolution: Strengthening Longitudinal Obesity Care

Question 1 of 21

According to the phase 3b ATTAIN-MAINTAIN trial, what was the primary efficacy outcome for patients who achieved a weight plateau on an injectable maximum tolerated dose (MTD) of tirzepatide or semaglutide, and were subsequently switched to oral orforglipron for weight maintenance?

A) Patients maintained 100% of their initial weight loss, identical to remaining on the injectable MTD.

B) Patients maintained 78% to 82% of the initial weight reduction achieved during the induction phase.

C) Patients regained over 50% of their initial weight within 24 weeks, triggering the need for rescue therapy.

D) Patients experienced an additive fat mass reduction of 15% combined with lean mass preservation.

E) The switch resulted in significant hepatic safety signals, requiring a return to injectable semaglutide.